Lymphadenopathy medical therapy

Jump to navigation Jump to search

Lymphadenopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lymphadenopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT scan

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lymphadenopathy medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lymphadenopathy medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lymphadenopathy medical therapy

CDC on Lymphadenopathy medical therapy

Lymphadenopathy medical therapy in the news

Blogs on Lymphadenopathy medical therapy

Directions to Hospitals Treating Lymphadenopathy

Risk calculators and risk factors for Lymphadenopathy medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]; Vendhan Ramanujam M.B.B.S [3]

Overview

Principles of Therapy

Medical management of lymphadenopathy depends on the underlying cause.

  • Antibiotics, antivirals, antifungals and antiparasitic medications are prescribed for infections due to bacteria, virus, fungi and parasites respectively.
  • Chemotherapy is instituted for those tumors that cannot be treated by surgery.
  • Radiation therapy is used in refractory tumors and metastatic tumors.

Therapy Based on Clinical Form

Generalized Lymphadenitis

Pathogen Based Therapy

▸ Click on the following categories to expand treatment regimens.[1]

Bacteria

  ▸  Group A Beta-Hemolytic Streptococci

  ▸  Mycobacterium Tuberculosis

  ▸  Brucella

  ▸  Leptospira

  ▸  Treponema pallidum

  ▸  Burkholderia

  ▸  Salmonella Typhi

Chlamydia

  ▸  Chlamydia Trachomatis

Fungi

  ▸  Histoplasma

  ▸  Cryptococcus Neoformans

Viral

  ▸  Measles Virus

  ▸  Rubella Virus

  ▸  Epstein-Barr Virus

  ▸  Cytomegalovirus

  ▸  Herpes Simplex Virus

  ▸  Human Immunodeficiency Virus

Protozoans

  ▸  Leishmania

  ▸  Trypanosoma

  ▸  Toxoplasma Gondii

Helminths

  ▸  Brugia Malayi

  ▸  Wuchereria Bancrofti

References

  1. Moran GJ, Abrahamian FM, Lovecchio F, Talan DA (2013). "Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines". J Emerg Med. 44 (6): e397–412. doi:10.1016/j.jemermed.2012.11.050. PMID 23466022.

Template:WH Template:WS